PUMA BIOTECHNOLOGY, INC. Earnings Per Share (Diluted)
PUMA BIOTECHNOLOGY, INC. (PBYI) reported Earnings Per Share (Diluted) of $0.16 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareDiluted · last filed 2026-08-06
- PUMA BIOTECHNOLOGY, INC. earnings per share, diluted for the quarter ending 2026-06-30 was $0.16, a 33.33% increase year-over-year.
- PUMA BIOTECHNOLOGY, INC. earnings per share, diluted for the quarter ending 2026-03-31 was -$0.07, a 216.67% decline year-over-year.
- PUMA BIOTECHNOLOGY, INC. earnings per share, diluted for the quarter ending 2025-12-31 was $0.26, a 33.47% decline year-over-year.
- PUMA BIOTECHNOLOGY, INC. earnings per share, diluted for the quarter ending 2025-09-30 was $0.17, a 58.54% decline year-over-year.
- PUMA BIOTECHNOLOGY, INC. earnings per share, diluted for fiscal 2025 was $0.61, a 1.61% decline from fiscal 2024.
- PUMA BIOTECHNOLOGY, INC. earnings per share, diluted for fiscal 2024 was $0.62, a 37.78% increase from fiscal 2023.
- PUMA BIOTECHNOLOGY, INC. earnings per share, diluted for fiscal 2023 was $0.45.
- PUMA BIOTECHNOLOGY, INC. earnings per share, diluted for fiscal 2022 was $0.00.
| Period end | Earnings Per Share, Diluted 3 month | Earnings Per Share, Diluted 6 month | Earnings Per Share, Diluted 9 month | Earnings Per Share, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.16 10-Q · filed 2026-08-06 | $0.08 10-Q · filed 2026-08-06 | $0.35 derived: net income ÷ weighted average shares · filed 2026-08-06 | $0.52 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2026-03-31 | -$0.07 10-Q · filed 2026-05-07 | $0.19 derived: net income ÷ weighted average shares · filed 2026-05-07 | $0.36 derived: net income ÷ weighted average shares · filed 2026-05-07 | $0.48 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2025-12-31 | $0.26 derived: net income ÷ weighted average shares · filed 2026-04-28 | $0.43 derived: net income ÷ weighted average shares · filed 2026-04-28 | $0.55 derived: net income ÷ weighted average shares · filed 2026-08-06 | $0.61 10-K · filed 2026-02-26 |
| 2025-09-30 | $0.17 10-Q · filed 2025-11-06 | $0.29 derived: net income ÷ weighted average shares · filed 2026-08-06 | $0.35 10-Q · filed 2025-11-06 | $0.74 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2025-06-30 | $0.12 10-Q · filed 2026-08-06 | $0.18 10-Q · filed 2026-08-06 | $0.57 derived: net income ÷ weighted average shares · filed 2026-08-06 | $0.98 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2025-03-31 | $0.06 10-Q · filed 2026-05-07 | $0.45 derived: net income ÷ weighted average shares · filed 2026-05-07 | $0.86 derived: net income ÷ weighted average shares · filed 2026-05-07 | $0.77 derived: net income ÷ weighted average shares · filed 2026-05-07 |
| 2024-12-31 | $0.39 derived: net income ÷ weighted average shares · filed 2026-04-28 | $0.80 derived: net income ÷ weighted average shares · filed 2026-04-28 | $0.72 derived: net income ÷ weighted average shares · filed 2026-04-28 | $0.62 10-K · filed 2026-02-26 |
| 2024-09-30 | $0.41 10-Q · filed 2025-11-06 | $0.32 derived: net income ÷ weighted average shares · filed 2025-11-06 | $0.22 10-Q · filed 2025-11-06 | $0.48 derived: net income ÷ weighted average shares · filed 2026-04-28 |
| 2024-06-30 | -$0.09 10-Q · filed 2025-08-07 | -$0.19 10-Q · filed 2025-08-07 | $0.06 derived: net income ÷ weighted average shares · filed 2026-04-28 | $0.18 derived: net income ÷ weighted average shares · filed 2026-04-28 |
| 2024-03-31 | -$0.10 10-Q · filed 2025-05-08 | $0.15 derived: net income ÷ weighted average shares · filed 2026-04-28 | $0.28 derived: net income ÷ weighted average shares · filed 2026-04-28 | $0.32 derived: net income ÷ weighted average shares · filed 2026-04-28 |
| 2023-12-31 | $0.26 derived: net income ÷ weighted average shares · filed 2026-04-28 | $0.38 derived: net income ÷ weighted average shares · filed 2026-04-28 | $0.42 derived: net income ÷ weighted average shares · filed 2026-04-28 | $0.45 10-K · filed 2026-02-26 |
| 2023-09-30 | $0.12 10-Q · filed 2024-11-07 | $0.17 derived: net income ÷ weighted average shares · filed 2024-11-07 | $0.20 10-Q · filed 2024-11-07 | $0.08 derived: net income ÷ weighted average shares · filed 2026-04-28 |
| 2023-06-30 | $0.05 10-Q · filed 2024-08-01 | $0.07 10-Q · filed 2024-08-01 | -$0.04 derived: net income ÷ weighted average shares · filed 2026-04-28 | -$0.05 derived: net income ÷ weighted average shares · filed 2026-04-28 |
| 2023-03-31 | $0.03 10-Q · filed 2024-05-02 | -$0.09 derived: net income ÷ weighted average shares · filed 2026-04-28 | -$0.10 derived: net income ÷ weighted average shares · filed 2026-04-28 | $0.10 derived: net income ÷ weighted average shares · filed 2026-04-28 |
| 2022-12-31 | -$0.12 derived: net income ÷ weighted average shares · filed 2026-04-28 | -$0.13 derived: net income ÷ weighted average shares · filed 2026-04-28 | $0.07 derived: net income ÷ weighted average shares · filed 2026-04-28 | $0.00 10-K · filed 2025-02-27 |
| 2022-09-30 | -$0.01 10-Q · filed 2023-11-02 | $0.20 derived: net income ÷ weighted average shares · filed 2023-11-02 | $0.13 10-Q · filed 2023-11-02 | $1.56 derived: net income ÷ weighted average shares · filed 2026-04-28 |
| 2022-06-30 | $0.21 10-Q · filed 2023-08-03 | $0.14 10-Q · filed 2023-08-03 | $1.60 derived: net income ÷ weighted average shares · filed 2026-04-28 | $0.56 derived: net income ÷ weighted average shares · filed 2026-04-28 |
| 2022-03-31 | -$0.08 10-Q · filed 2023-05-04 | $1.42 derived: net income ÷ weighted average shares · filed 2026-04-28 | $0.35 derived: net income ÷ weighted average shares · filed 2026-04-28 | $0.23 derived: net income ÷ weighted average shares · filed 2026-04-28 |
| 2021-12-31 | $1.52 derived: net income ÷ weighted average shares · filed 2026-04-28 | $0.44 derived: net income ÷ weighted average shares · filed 2026-04-28 | $0.31 derived: net income ÷ weighted average shares · filed 2026-04-28 | -$0.72 10-K · filed 2024-02-29 |
| 2021-09-30 | -$1.09 10-Q · filed 2022-11-03 | -$1.22 derived: net income ÷ weighted average shares · filed 2022-11-03 | -$0.82 10-Q · filed 2022-11-03 | -$1.19 derived: net income ÷ weighted average shares · filed 2022-11-03 |
| 2021-06-30 | -$0.13 10-Q · filed 2022-08-04 | $0.28 10-Q · filed 2022-08-04 | -$0.09 derived: net income ÷ weighted average shares · filed 2022-08-04 | -$0.87 derived: net income ÷ weighted average shares · filed 2022-08-04 |
| 2021-03-31 | $0.40 10-Q · filed 2022-05-05 | $0.04 derived: net income ÷ weighted average shares · filed 2022-05-05 | -$0.75 derived: net income ÷ weighted average shares · filed 2022-05-05 | -$0.66 derived: net income ÷ weighted average shares · filed 2022-05-05 |
| 2020-12-31 | -$0.38 10-K · filed 2021-03-01 | -$1.17 derived: net income ÷ weighted average shares · filed 2021-11-04 | -$1.08 derived: net income ÷ weighted average shares · filed 2021-11-04 | -$1.52 10-K · filed 2023-03-02 |
| 2020-09-30 | -$0.79 10-Q · filed 2021-11-04 | -$0.70 derived: net income ÷ weighted average shares · filed 2021-11-04 | -$1.14 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $0.08 10-Q · filed 2021-08-05 | -$0.34 10-Q · filed 2021-08-05 | ||
| 2020-03-31 | -$0.43 10-Q · filed 2021-05-06 | |||
| 2019-06-30 | -$0.97 10-Q · filed 2020-08-06 | -$1.23 10-Q · filed 2020-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |